Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)
CNY 15.64
(0.77%)
CNY 15.64
(0.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 477.37 Million CNY | -25.58% |
| 2022 | 175.15 Million CNY | 13.67% |
| 2021 | 197.64 Million CNY | 28.27% |
| 2020 | 83.6 Million CNY | -45.52% |
| 2019 | 272.16 Million CNY | 7.74% |
| 2018 | 271.43 Million CNY | 44.84% |
| 2017 | 192.41 Million CNY | -6.21% |
| 2016 | 184.88 Million CNY | 20.52% |
| 2015 | 164.16 Million CNY | 19.87% |
| 2014 | 136.05 Million CNY | -62.02% |
| 2013 | 376.02 Million CNY | -3.14% |
| 2012 | 387.96 Million CNY | -3.64% |
| 2011 | 406.11 Million CNY | 42.82% |
| 2010 | 285.13 Million CNY | 26.37% |
| 2009 | 225.01 Million CNY | 12.02% |
| 2008 | 198.06 Million CNY | 19.03% |
| 2007 | 169.87 Million CNY | 60.9% |
| 2006 | 104.88 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 65.68 Million CNY | 165.36% |
| 2024 Q2 | 58.92 Million CNY | 4.96% |
| 2024 Q3 | 11.15 Million CNY | -86.55% |
| 2023 Q4 | -76.46 Thousand CNY | -100.13% |
| 2023 FY | - CNY | -25.58% |
| 2023 Q1 | 56.27 Million CNY | 68.94% |
| 2023 Q2 | 49.95 Million CNY | -11.22% |
| 2023 Q3 | 60.31 Million CNY | 20.73% |
| 2022 Q1 | 50.86 Million CNY | 52.52% |
| 2022 FY | - CNY | 13.67% |
| 2022 Q4 | 33.31 Million CNY | -36.93% |
| 2022 Q3 | 52.81 Million CNY | 36.59% |
| 2022 Q2 | 38.66 Million CNY | -23.98% |
| 2021 Q1 | 43.87 Million CNY | 736.66% |
| 2021 Q2 | 31.43 Million CNY | -28.35% |
| 2021 Q3 | 44.59 Million CNY | 41.86% |
| 2021 Q4 | 33.34 Million CNY | -25.22% |
| 2021 FY | - CNY | 28.27% |
| 2020 Q1 | 40.99 Million CNY | -48.54% |
| 2020 Q2 | 27.63 Million CNY | -32.59% |
| 2020 Q3 | 28.46 Million CNY | 3.01% |
| 2020 Q4 | 5.24 Million CNY | -81.58% |
| 2020 FY | - CNY | -45.52% |
| 2019 Q4 | 79.67 Million CNY | 44.04% |
| 2019 Q1 | 53.76 Million CNY | -45.86% |
| 2019 FY | - CNY | 7.74% |
| 2019 Q3 | 55.31 Million CNY | 0.71% |
| 2019 Q2 | 54.92 Million CNY | 2.15% |
| 2018 Q4 | 99.31 Million CNY | 126.59% |
| 2018 FY | - CNY | 44.84% |
| 2018 Q3 | 43.83 Million CNY | -7.77% |
| 2018 Q2 | 47.52 Million CNY | 28.19% |
| 2018 Q1 | 37.07 Million CNY | 38.06% |
| 2017 FY | - CNY | -6.21% |
| 2017 Q1 | 44.86 Million CNY | -35.81% |
| 2017 Q3 | 21.25 Million CNY | -55.7% |
| 2017 Q4 | 26.85 Million CNY | 26.35% |
| 2017 Q2 | 47.96 Million CNY | 6.92% |
| 2016 FY | - CNY | 20.52% |
| 2016 Q1 | 45.94 Million CNY | 75.62% |
| 2016 Q3 | 12.36 Million CNY | -65.61% |
| 2016 Q2 | 35.95 Million CNY | -21.75% |
| 2016 Q4 | 69.89 Million CNY | 465.27% |
| 2015 FY | - CNY | 19.87% |
| 2015 Q2 | 70.09 Million CNY | 31.16% |
| 2015 Q3 | 13.2 Million CNY | -81.17% |
| 2015 Q4 | 26.16 Million CNY | 98.17% |
| 2015 Q1 | 53.44 Million CNY | 405.46% |
| 2014 Q2 | 38.67 Million CNY | -46.98% |
| 2014 Q4 | 10.57 Million CNY | 186.55% |
| 2014 Q3 | 3.68 Million CNY | -90.46% |
| 2014 Q1 | 72.94 Million CNY | -4.57% |
| 2014 FY | - CNY | -62.02% |
| 2013 Q3 | 64.23 Million CNY | -47.74% |
| 2013 Q2 | 122.92 Million CNY | 0.41% |
| 2013 FY | - CNY | -3.14% |
| 2013 Q4 | 76.44 Million CNY | 19.0% |
| 2013 Q1 | 122.41 Million CNY | 100.27% |
| 2012 Q1 | 109.59 Million CNY | -35.68% |
| 2012 Q4 | 61.12 Million CNY | -28.51% |
| 2012 Q3 | 85.5 Million CNY | -22.33% |
| 2012 Q2 | 110.08 Million CNY | 0.44% |
| 2012 FY | - CNY | -3.64% |
| 2011 Q2 | 195.29 Million CNY | 103.99% |
| 2011 Q1 | 95.73 Million CNY | 129.37% |
| 2011 Q4 | 170.38 Million CNY | 279.29% |
| 2011 FY | - CNY | 42.82% |
| 2011 Q3 | 44.92 Million CNY | -77.0% |
| 2010 Q2 | 72.4 Million CNY | -23.67% |
| 2010 FY | - CNY | 26.37% |
| 2010 Q3 | 60.98 Million CNY | -15.78% |
| 2010 Q4 | 41.73 Million CNY | -31.56% |
| 2010 Q1 | 94.85 Million CNY | 428.44% |
| 2009 Q4 | 17.95 Million CNY | -58.07% |
| 2009 Q1 | 78.75 Million CNY | 0.0% |
| 2009 Q2 | 68.01 Million CNY | -13.64% |
| 2009 FY | - CNY | 12.02% |
| 2009 Q3 | 42.81 Million CNY | -37.05% |
| 2008 FY | - CNY | 19.03% |
| 2007 FY | - CNY | 60.9% |
| 2006 FY | - CNY | 0.0% |